Seldane®

Hoescht Marion Roussel and Baker Norton Pharmaceuticals have voluntarily discontinued distribution and marketing of all terfenadine-containing antihistamine product lines in the United States.

Terfenadine-containing products, such as SeldaneŽ and SeldaneŽ-D, have been associated with rare, but serious heart problems when taken with certain other drugs, including certain antibiotics and antifungals.

In January 1997, FDA proposed removing all terfenadine products from the marketplace because of the approval of a safer alternative drug: Allegra (fexofenadine hydrochloride). Fexofenadine hydrochloride provides exactly the same benefits of terfenadine, but it does not cause a potentially fatal heart condition when taken with certain other commonly prescribed medications. At that time, FDA advised patients currently taking SeldaneŽ, SeldaneŽ-D and generic terfenadine products to talk to their health care providers about switching to alternative medications. Following the approval of Allegra-D in December 1997 and with the prior approval of Allegra, Hoescht Marion Roussel announced its plans to discontinue distribution and marketing of the drugs' predecessors, SeldaneŽ and SeldaneŽ-D from the marketplace as of Feb. 1. Likewise, the manufacturer of generic terfenadine, Baker Norton Pharmaceuticals, also has discontinued U.S. distribution and marketing of its product.

Source: fda.gov

If you or a loved one has been harmed by SeldaneŽ, you may want to contact a SeldaneŽ attorney for more information.